A Phase 3 interventional study of Technosphere® Insulin and Usual Care in Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus and Moderate Chronic Obstructive Pulmonary Disease, sponsored by Mannkind Corporation. Terminated at 21 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-04-14.
Sponsored by Mannkind Corporation · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 35 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 1 — 1 open to participants now, 1 under way, none of them phase 3. Insulin, Regular, Human · Diabetes Mellitus, Type 1.
Among the 35 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 1, this one is the 21st largest by enrollment, is the only one that started in 2009, is one of 17 in phase 3, and was the 18th registered.
3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →1 of the 35 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 1 is open now, in 1 country. Recruiting first, the newest first:
Mannkind Corporation · Sites in United States
Ages 6–17
By country, each count listing its studies:
Insulin, Regular, Human: first FDA approval 1982 (HUMULIN R PEN), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →
Of the 414 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 260 (63%) stop at 75 or younger; 187 take children under 18; 64 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
35 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 9 · Phase 3 17 · Phase 4 4
First in 1989; this study’s year is marked. 1 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 34 is below the median of 40 across 2,821 interventional studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 74 across the 35 interventional studies. Of the 34 that completed or were terminated, 10 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
31 of 35 have an industry lead sponsor. The 10 most frequent:
Mannkind Corporation is the lead sponsor of 57 studies on the registry; 3 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 3 (38%) have results posted.
21 studies in Diabetes Mellitus, Type 1 by Mannkind Corporation: 1 open now, 1 under way, none of them phase 3. Of 19 finished, 10 (53%) have results posted.
Among the 21 studies in Diabetes Mellitus, Type 1 by Mannkind Corporation, this one is the 9th largest by enrollment of the 18 interventional ones that give a count, is the only one that started in 2009, is one of 7 in phase 3, and was the 5th registered.
Mannkind Corporation’s Diabetes Mellitus, Type 1 studies by the year they started, since 2005.
1 of the studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 1 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07224321Mannkind CorporationINHALE-1st: Afrezza® For Youth With Newly-Diagnosed Type 1 Diabetes | 2027-03 |
Add it to your calendar (.ics) → With an account.
Among the 35 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 1, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Mannkind Corporation’s 21 in Diabetes Mellitus, Type 1:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Examine the effects of TI in combination with an anti-diabetic regimen including inhaled insulin versus anti-diabetic treatment without inhaled insulin on lung function \& pulmonary safety
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Asthma
Both
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Technosphere® Insulin Inhalation Powder administered prandially in diabetic participants with Asthma
Drug: Technosphere® Insulin
Usual anti diabetic care in Diabetic participants with Asthma
Drug: Usual Care
Technosphere® Insulin Inhalation Powder administered prandially in diabetic participants with Chronic Obstructive Pulmonary disease (COPD)
Drug: Technosphere® Insulin
Usual anti diabetic care in Diabetic participants with Chronic Obstructive Pulmonary disease (COPD)
Drug: Usual Care
Technosphere® Insulin delivered with Gen 2 inhaler with doses individualized for each participant in combination with an antidiabetic regimen of insulin and/or oral antidiabetic agents
Also known as: Afrezza
Type 1 diabetics: long-acting (basal) insulin plus rapid-acting insulin, or pre-mix insulin Type 2 diabetics: oral anti-diabetic medications with or without long-acting (basal) insulin
Change in Post-bronchodilator FEV1 From Baseline to Week 52
Post-bronchodilator Forced Expiratory Volume in 1 second (FEV1) is measured at the pulmonary function laboratory.
Time frame: 52 Weeks
Number of Participants With Asthma Exacerbation by Treatment Arm
Number of participants who experienced worsening of asthma symptoms
Time frame: Baseline to Week 52
Number of Participants With COPD Exacerbation by Treatment Arm
Number of participants who experienced worsening of COPD symptoms
Time frame: Baseline to Week 52
Change in HbA1C From Baseline to Week 52
Time frame: Baseline, week 52
A total of 517 participants were screened in 5 countries . First participant was screened in March 2009.
| Milestone | Technosphere® Insulin (Asthma) | Usual Care (Asthma) | Technosphere® Insulin (COPD) | Usual Care (COPD) |
|---|---|---|---|---|
| Started | 9 | 8 | 9 | 8 |
| Completed | 0 | 1 | 0 | 1 |
| Not completed | 9 | 7 | 9 | 7 |
| Withdrew: Adverse event | 2 | 0 | 1 | 0 |
| Withdrew: Study terminated by sponsor | 7 | 6 | 4 | 5 |
| Withdrew: Withdrawal by subject | 0 | 1 | 1 | 1 |
| Withdrew: Protocol violation | 0 | 0 | 2 | 0 |
| Withdrew: Physician decision | 0 | 0 | 1 | 1 |
Post-bronchodilator Forced Expiratory Volume in 1 second (FEV1) is measured at the pulmonary function laboratory.
No measurements were reported for this outcome.
Number of participants who experienced worsening of asthma symptoms
| participants | Technosphere® Insulin (Asthma) | Usual Care With Anti-diabetic Agents (Asthma) | Technosphere® Insulin (COPD) | Usual Care With Anti-diabetic Agents (COPD) |
|---|---|---|---|---|
| Exacerbation of Asthma | 1 | 1 | — | — |
| No Exacerbation of Asthma | 8 | 7 | — | — |
Number of participants who experienced worsening of COPD symptoms
| participants | Technosphere® Insulin (Asthma) | Usual Care With Anti-diabetic Agents (Asthma) | Technosphere® Insulin (COPD) | Usual Care With Anti-diabetic Agents (COPD) |
|---|---|---|---|---|
| COPD Exacerbation | — | — | 3 | 1 |
| No Exacerbation | — | — | 6 | 7 |
No measurements were reported for this outcome.
Collected over All Adverse Events (AE) were collected from signature of the informed consent form up to 30 days after the last study visit or study related procedure was performed regardless of seriousness or relationship to investigational product. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Technosphere® Insulin (Asthma) | — | 2/9 (22.2%) | 8/9 (88.9%) |
| Usual Care With Anti-diabetic Agents (Asthma) | — | 0/8 (0%) | 7/8 (87.5%) |
| Technosphere® Insulin (COPD) | — | 0/9 (0%) | 4/9 (44.4%) |
| Usual Care With Anti-diabetic Agents (COPD) | — | 0/8 (0%) | 6/8 (75%) |
| Event | Technosphere® Insulin (Asthma) | Usual Care With Anti-diabetic Agents (Asthma) | Technosphere® Insulin (COPD) | Usual Care With Anti-diabetic Agents (COPD) |
|---|---|---|---|---|
| AsthmaRespiratory, thoracic and mediastinal disorders | 1/9 | 0/8 | 0/9 | 0/8 |
| Intestinal obstructionGastrointestinal disorders | 1/9 | 0/8 | 0/9 | 0/8 |
| HypercalcaemiaMetabolism and nutrition disorders | 1/9 | 0/8 | 0/9 | 0/8 |
| HypoglycaemiaMetabolism and nutrition disorders | 1/9 | 0/8 | 0/9 | 0/8 |
| B-cell lymphomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/9 | 0/8 | 0/9 | 0/8 |
| Event | Technosphere® Insulin (Asthma) | Usual Care With Anti-diabetic Agents (Asthma) | Technosphere® Insulin (COPD) | Usual Care With Anti-diabetic Agents (COPD) |
|---|---|---|---|---|
| HypoglycemiaMetabolism and nutrition disorders | 2/9 | 0/8 | 1/9 | 3/8 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 0/9 | 0/8 | 3/9 | 1/8 |
| Urinary Tract InfectionInfections and infestations | 0/9 | 2/8 | 0/9 | 0/8 |
| BronchitisInfections and infestations | 2/9 | 0/8 | 0/9 | 0/8 |
| CoughRespiratory, thoracic and mediastinal disorders | 1/9 | 0/8 | 2/9 | 0/8 |
| AstheniaGeneral disorders | 0/9 | 1/8 | 0/9 | 0/8 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 0/9 | 1/8 | 0/9 | 0/8 |
| Diabetes mellitusMetabolism and nutrition disorders | 0/9 | 1/8 | 0/9 | 0/8 |
| DyslipidaemiaMetabolism and nutrition disorders | 0/9 | 1/8 | 0/9 | 0/8 |
| Hot flushVascular disorders | 0/9 | 1/8 | 0/9 | 0/8 |
Subjects who received at least one dose of study medication
| Age, Continuous(years) | Technosphere® Insulin (Asthma) | Usual Care (Asthma) | Technosphere® Insulin (COPD) | Usual Care (COPD) | Total |
|---|---|---|---|---|---|
| Mean | 69.00 ± 7.26 | 49.75 ± 15.73 | 67.44 ± 8.38 | 68.88 ± 8.20 | 64.03 ± 12.71 |
| Sex: Female, Male(Participants) | Technosphere® Insulin (Asthma) | Usual Care (Asthma) | Technosphere® Insulin (COPD) | Usual Care (COPD) | Total |
|---|---|---|---|---|---|
| Female | 6 | 4 | 2 | 1 | 13 |
| Male | 3 | 4 | 7 | 7 | 21 |
The record gives a start of Mar 2009, a primary completion of Nov 2014 and a completion of Nov 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2016, 1 year 3 months after primary completion. A results delay was requested in Jun 2009.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Insulin, Regular, Human